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Summary
Homocystinuria due to cystathionine b-synthase (CBS)
deficiency, inherited as an autosomal recessive trait, is
the most prevalent inborn error of methionine metab-
olism. Its diverse clinical expression may include ectopia
lentis, skeletal abnormalities, mental retardation, and
premature arteriosclerosis and thrombosis. This varia-
bility is likely caused by considerable genetic heteroge-
neity. We investigated the molecular basis of CBS defi-
ciency in 29 Dutch patients from 21 unrelated pedigrees
and studied the possibility of a genotype-phenotype re-
lationship with regard to biochemical and clinical ex-
pression and response to homocysteine-lowering treat-
ment. Clinical symptoms and biochemical parameters
were recorded at diagnosis and during long-term follow-
up. Of 10 different mutations detected in the CBS gene,
833TrC (I278T) was predominant, present in 23 (55%)
of 42 independent alleles. At diagnosis, homozygotes for
this mutation ( ) tended to have higher homocy-n  12
steine levels than those seen in patients with other gen-
otypes ( ), but similar clinical manifestations.Dur-n  17
ing follow-up, I278T homozygotes responded more
efficiently to homocysteine-lowering treatment. After
378 patient-years of treatment, only 2 vascular events
were recorded; without treatment, at least 30 would
have been expected ( ). This intervention in DutchP ! .01
patients significantly reduces the risk of cardiovascular
disease and other sequelae of classical homocystinuria
syndrome.
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Introduction
Homocystinuria due to cystathionine b-synthase (CBS;
L-serine hydrolyase [adding homocysteine]) deficiency
(MIM 236200) is the most common inborn error in
methionine metabolism. CBS is a pyridoxal 5′-phosphate
(PLP)–dependent enzyme and condenses homocysteine
and serine to cystathionine, an irreversible step in trans-
sulfuration (Mudd et al. 1995).
Carson and Neill (1962) first described homocystin-
uria in mentally retarded individuals in Northern Ire-
land. Soon thereafter, it was shown that the primary
defect in homocystinuria was an enzymatic defect of CBS
(Mudd et al. 1964), with a recessive mode of inheritance
(Finkelstein et al. 1964). The clinical manifestation of
CBS deficiency is diverse, and four major organ systems
are predominantly involved: the eye (high myopia and
ectopia lentis), the skeleton (osteoporosis, scoliosis, and
Marfanoid features), the vascular system (premature ar-
teriosclerosis and thromboembolism), and the CNS
(mental retardation, convulsions, and psychiatric dis-
turbances).
Biochemically, patients with CBS deficiency are char-
acterized by severe hyperhomocysteinemia and homo-
cystinuria, hypermethioninemia, and decreased plasma
cysteine levels. Furthermore, the CBS activitiesmeasured
in either liver biopsy specimens (Mudd et al. 1964), cul-
tured fibroblasts (Uhlendorf and Mudd 1968), or phy-
tohemagglutinin-stimulated lymphocytes (Goldstein et
al. 1972) are mostly well below the range of CBS activ-
ities observed in controls and heterozygotes for CBS de-
ficiency. The first choice of therapy in CBS-deficient pa-
tients consists of administration of supraphysiological
doses of pyridoxine (vitamin B6), the precursor of PLP,
the cofactor of CBS. A large international survey of 1600
patients with homocystinuria showed that ∼50% of the
patients responded to high doses of pyridoxine with a
substantial reduction in blood homocysteine concentra-
tions (Mudd et al. 1985). Pyridoxine-nonresponsive pa-
tients usually are more severely affected than pyridoxine-
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Table 1
CBS Mutations in Dutch Homocystinurics
DNA
Mutation
Amino Acid
Substitution RFLP Frequencya
373CrT R125W AciI 1/42
456CrG I152M Sau3A 3/42
494GrA C165Y BsoFI 4/42
539TrC V180A HhaI 1/42
833TrC I278T BsrI 23/42
1105CrTb R369C HhaI 2/42
1111GrA V371M NlaIII 2/42
1301CrA T434N None 1/42
1330GrA D444N TaqI 2/42
1471CrTb R491C BglII 2/42
a In independent alleles.
b Mutations were observed in cis in one patient.
responsive patients and are concomitantly treated with
combinations of folic acid, hydroxycobalamin, and be-
taine, to stimulate remethylation of homocysteine to
methionine.
Data on the clinical efficacy of homocysteine-lowering
treatment are scarce. In pyridoxine-responsive patients
and early-treated pyridoxine-nonresponsive patients,
such treatment has reduced the number of initial throm-
boembolic events (Mudd et al. 1985). A recent report
by Wilcken and Wilcken (1997) showed that treatment
that effectively lowered plasma homocysteine concen-
trations markedly reduced the cardiovascular risk in a
group of 32 patients with pyridoxine-responsive and
pyridoxine-nonresponsive homocystinuria.
The human CBS gene, which has been mapped to
21q22.3 (Mu¨ncke et al. 1988), encodes a CBS subunit
of 63 kD, which assembles into a homotetrameric pro-
tein (Kraus et al. 1978). So far, 160 mutations have been
detected in the CBS gene (Kraus 1998), and functional
relevance has been tested for some of them in either a
bacterial (de Franchis et al. 1994; Marble et al. 1994;
Kluijtmans et al. 1996a) or a yeast (Kruger and Cox
1995) expression system. Althoughmostmutations seem
to be private or restricted to only a few pedigrees, three
mutations are relatively common among patients with
homocystinuria. An 833TrC transition (I278T) (Kozich
and Kraus 1992) has been found in alleles from hom-
ocystinuric patients of different ethnic backgrounds and
has been reported to be associated with pyridoxine re-
sponsiveness and a relatively mild clinical phenotype
when present in homozygous state (Shih et al. 1995).
On the other hand, a 919GrA transition (G307S) is
related to a more severe clinical phenotype and has been
detected mainly in alleles from homocystinuric patients
of Celtic origin (Gallagher et al. 1995). A third relatively
common CBS mutation, an IVS11-2ArC splice muta-
tion, which results in skipping exon 12, has been de-
tected in patients from Central and Eastern Europe
(Kraus 1998).
In the present study, we investigated the molecular
basis of homocystinuria due to CBS deficiency in 29
Dutch homocystinuria patients from 21 unrelated ped-
igrees, and we studied a possible relationship between
CBS genotype and biochemical and clinical phenotype.
We therefore measured homocyst(e)ine concentrations
at diagnosis, upon pyridoxine treatment, and uponmax-
imal treatment, with pyridoxine and folic acid, with or
without betaine, and then recorded whether homocy-
steine-lowering treatment had been able to prevent fur-
ther clinical events or symptoms.
Patients, Material, and Methods
Patients
We studied 29 patients with homocystinuria due to
CBS deficiency, from 21 unrelated pedigrees. Patients
were initially diagnosed on the basis of clinical mani-
festations of homozygous CBS deficiency, in combina-
tion with a quantitative determination of severe hyper-
homocysteinemia and hypermethioninemia. In two
patients (19 and 29), the diagnosis was made only on
the basis of severe homocystinuria, which was demon-
strated by qualitative urine analyses. Homozygous CBS
deficiency in these two patients has been confirmed by
detection of a homozygous mutation (patient 19) and
by the clinical manifestation of ectopia lentis (19 and
29), never observed in heterozygotes for CBS deficiency.
Furthermore, the parents of patient 29 showed an ab-
normal response to a methionine-loading test, compa-
rable to that observed in obligate heterozygotes. Hom-
ocysteine-lowering treatment was initiated in all patients
immediately after the diagnosis had been made. Each
patient was seen on a regular basis (once or twice each
year) by two of us (Boers and Cruysberg), and the bi-
ochemical efficacy of homocysteine-lowering therapy
was determined by measurement of homocyst(e)ine and
methionine in blood. At diagnosis and during long-term
follow-up, clinical manifestations were recorded by
means of routine clinical, radiographic, or scintigraphic
examination procedures.
Pyridoxine Responsiveness
Pyridoxine responsiveness was examined after 6
weeks of treatment with vitamin B6, 750 mg/day in
adults or 200–500 mg/day in children. Patients in whom
non–protein-bound serum homocysteine had decreased
to !20 mmol/L, or total plasma homocysteine (protein-
and non–protein-bound) to !50 mmol/L, were classified
as pyridoxine responsive. All other patients were cate-
gorized as pyridoxine-nonresponsive homocystinurics.
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Biochemical Analysis
Homocystine, homocysteine-cysteine–mixeddisulfide,
and methionine levels in serum were determined as de-
scribed by Boers et al. (1983). The amount of
non–protein-bound homocysteine was calculated as the
sum of twice the concentration of homocystine plus the
concentration of the homocysteine-cysteine–mixed di-
sulfide moiety. Since 1990, total plasma homocysteine
concentrations (i.e., the total amount of protein- and
non–protein-bound homocysteine moieties) were deter-
mined as described by Te Poele-Pothoff et al. (1995).
CBS activities in extracts of cultured fibroblasts were
measured as initially described by Fowler et al. (1978),
with some modifications (Boers et al. 1985). These CBS
activities were measured with and without addition of
1 mM PLP to the incubation mixture.
Mutation Analysis
The procedure for mutation analysis of the CBS gene
in patients with homocystinuria has been described else-
where (Kluijtmans et al. 1996a). In brief, genomic DNA
was isolated from peripheral blood leukocytes (Miller
et al. 1988) and stored at 4C. Total RNA was extracted
from cultured fibroblasts by the method of Chomczynski
and Sacchi (1987) and was stored as an ethanol precip-
itate at 80C. We used 1–5 mg total RNA for first-
strand cDNA synthesis with Superscript II Reverse Tran-
scriptase (Life Technologies). First-strand cDNA was
used as a template in PCR amplification reactions to
amplify the CBS-encoding region inmultiple overlapping
cDNA fragments. These fragments were subsequently
sequenced on an ABI 377 automated DNA sequencer
(Applied Biosystems) with the Taq Dye Deoxy Termi-
nator Cycle Sequencing Kit. All cDNA fragments were
sequenced on both strands, and mutations were con-
firmed at the genomic DNA level by restriction enzyme
analysis or DNA sequencing. Restriction enzymes were
purchased from Life Technologies or from New England
Biolabs and were used according to the manufacturers’
recommendations. Screening for 833TrC was per-
formed as described elsewhere (Kluijtmans et al. 1996b).
Using this procedure, we were able to discriminate be-
tween the real 833TrC carriers and those with an
844ins68 duplication variant (Sebastio et al. 1995).
Cloning and Expression of Mutations
cDNA fragments containing the presumed functional
mutations were amplified by PCR and subcloned into
an expression cartridge as described elsewhere (de Fran-
chis et al. 1994). Recombinant clones were selected and
sequenced to verify the integrity of the cloned fragment.
CBS expression was induced upon addition of isopropyl-
b-thiogalactopyranoside (Kozich and Kraus 1992). The
CBS assay was performed without addition of bovine
serum albumin to the incubation mixture, to which cys-
tathionine was added at a final concentration of 2 mM.
Statistics
Differences in clinical manifestation of CBS deficiency
and efficacy of homocysteine-lowering treatment be-
tween separate groups were assessed by Yates’ corrected
x2 test. Differences in age at diagnosis, homocysteine,
and methionine concentrations were assessed by non-
parametric Wilcoxon–Mann-Whitney U tests. All P val-
ues reported are two-tailed, and was consideredP ! .05
statistically significant.
Results
Study Group
Twenty-nine homocystinuria patients from 21 pedi-
grees were included in this study. Six families had two
affected siblings; one family had three affected siblings.
The male–female ratio was 16:13. The diagnosis of CBS
deficiency was established at a mean age of 26 years
(median, 23 years [range 4–60]).
Genetic Basis of Homocystinuria
The CBS gene of the patients with homocystinuriawas
analyzed for mutations, either by direct sequencing of
reverse transcription–PCR–amplified fragments (in 14
patients) or by RFLP analysis of genomic DNA frag-
ments, to screen for previously recognized mutations (in
15 patients). The molecular basis of homocystinuria was
resolved in 25 (86%) of the 29 patients. Overall, 10
different mutations were found (table 1), of which the
833TrC mutation was the most prevalent. This muta-
tion was observed in 23 (55%) of 42 independent alleles.
In four patients, including one in whom the entire cDNA
was sequenced, only one mutation in heterozygous state
was found; the mutation in the second allele has yet to
be found (table 2).
CBS Activities in Cultured Fibroblasts
CBS activities were measured in extracts of cultured
fibroblasts in 12 healthy controls, in 9 CBS-deficient pa-
tients homozygous for I278T, and in 12 patients with
another CBS genotype (table 2). Without PLP addition
to the incubation mixture, the mean ( SD) CBS activity
in homozygotes was .17 ( .37) nmol cystathionine/mg
protein/h, !2.5% of the control mean (7.4 [ 5.1] nmol
cystathionine/mg protein/h). One homocystinuric pa-
tient (18) clearly exhibited CBS activities, in the range
of obligate heterozygotes, and has been described else-
where (Kluijtmans et al. 1996a).
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Table 2
The Molecular Basis of Homocystinuria Due to CBS Deficiency
SIBSHIP PATIENT CODE
PYRIDOXINE
RESPONSIVENESS
CBS ACTIVITYa
(NMOL CYSTATHIONINE/
MG PROTEIN/H) MUTATION
 PLPb  PLP Allele 1 Allele 2
1 1 HvE51  ND ND C165Y I278T
2 HvE53  .06 0 C165Y I278T
3 vU58  ND ND C165Y I278T
2 4 AB58  .32 .31 C165Y Unidentified
5 RB61  ND ND C165Y Unidentified
3 6 Gr32  0 .12 I278T I278T
7 BGr28  0 .24 I278T I278T
4 8 JJ68  ND ND I278T I278T
9 WSJ63  ND ND I278T I278T
5 10 BH50  .05 .38 I278T I278T
11 HH49  ND ND I278T I278T
6 12 MC62 ND .08 1.03 I152M I278T
13 JC70 ND .06 1.08 I152M I278T
7 14 RvD66  .25 .31 R125W T434N
15 HvD67  0 0 R125W T434N
8 16 YvH75 ND 0 0 I278T I278T
9 17 AP67  0 .24 C165Y C165Y
10 18 JL75  1.74 2.60 D444N D444N
11 19 MK66  .62 .77 I152M I152M
12 20 LK61  .12 .20 I278T I278T
13 21 LH80 ND .18 .26 I278T I278T
14 22 GMV29  .09 .67 R369C 
R491C
R369C 
R491C
15 23 CE38  0 0 I278T I278T
16 24 RB58  0 0 I278T I278T
17 25 AdZ46  .06 .42 V180A Unidentified
18 26 JM61  0 .12 I278T V371M
19 27 JU78  .07 0 I278T I278T
20 28 JR42 ND .03 .08 I278T V371M
21 29 RP72 ND ND ND I278T Unidentified
NOTE.—A plus sign () indicates pyridoxine responsive, and a minus sign () indicates pyridoxine non-
responsive; ND  not determined.
a Cystathionine b-synthase activity expressed in nmol cystathionine formed/mg protein/h.
b Mean ( SD) CBS activity in fibroblasts of healthy controls: 7.4 ( 5.1).
The mean CBS activity in fibroblasts of homozygotes
for I278T ( ) versus patients with other genotypesn  9
( ) was versus nmol cys-n  12 0.05 0.07 0.13 0.18
tathionine/mg protein/h ( ), and ver-P  .28 0.13 0.14
sus nmol cystathionine/mg protein/h (0.42 0.38 P 
) in the assay without and with, respectively, 1 mM.07
PLP. Patient 18 was excluded in these calculations.
In Vitro Expression of Mutations
The functional relevance of seven mutations was in-
vestigated in an Escherichia coli expression system: six
constructs contained a single mutation, and one con-
struct contained the 1105CrT (R369C) and 1471CrT
(R491C) mutations in cis.All mutated constructs, except
the one containing 1330GrA (D444N) (Kluijtmans et
al. 1996a), showed a reduction in CBS activity of 190%,
demonstrating the detrimental effects of each construct
on CBS activity (fig. 1). Two mutations (373CrT
[R125W] and 1301CrA [T434N]) have not yet been
functionally tested.
Pyridoxine Responsiveness
Fourteen (48%) of 29 patients were classified as pyr-
idoxine responsive and 9 (31%) patients as pyridoxine
nonresponsive, on the basis of the criteria described in
the Patients, Material, and Methods section. In six pa-
tients (12, 13, 16, 21, 28, and 29), responsiveness to
pyridoxine alone could not be assessed. In view of their
extremely high homocysteine levels at diagnosis, these
patients were treated directly with a combination of ther-
apeutic regimens (pyridoxine and folic acid, with or
without betaine). Pyridoxine responders were diagnosed
at a mean age of 29 years (median, 26 years [range,
7–54 years]), and nonresponders at a mean age of 19
years (median, 16 years [range, 4–30 years]; ).P  .08
Seven (58%) of 12 homozygotes for the I278T mu-
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Figure 1 CBS activities measured in anE. coli expression system.
Mutations were introduced as described in the Patients, Material, and
Methods section. Bacterial lysates were assayed for CBS activity, and
the mean CBS activity of a control construct (40.3 nmol cystathionine
formed/mg protein/h) has been set to 100%. Each bar represents an-
other mutated construct and is the mean of two independently per-
formed CBS assays.
tation showed in vivo pyridoxine responsiveness, 3
(25%) were nonresponders, and, in 2 (17%) patients,
this specific responsiveness could not be assessed. In 17
individuals with other genotype combinations, including
compound heterozygotes for I278T, these numbers were
7 (41%), 6 (35%), and 4 (24%), respectively ( 2x 
; ). Conversely, in 14 pyridoxine-responsive0.13 P  .7
patients, 18 (64%) of 28 alleles carried the I278T mu-
tation (7 homozygotes, 4 heterozygotes), versus 6 (33%)
I278T alleles in 9 nonresponsive patients (3 homozy-
gotes) ( ; ). There was an absolute con-2x  1.39 P  .5
cordance of pyridoxine responsiveness between siblings.
Clinical Characteristics at Diagnosis
The clinical manifestation of homocystinuria due to
CBS deficiency in this study group is very diverse and is
depicted in detail in table 3. At diagnosis, some patients
(2, 13, and 15) showed virtually no clinical symptoms
and were investigated because of a homocystinuric sib-
ling. In other patients (6, 19, 22, 23, and 25), all four
major organ systems were involved. Ocular abnormal-
ities and skeletal abnormalities were the most consistent
findings among these 29 patients with homocystinuria:
25 (86%) suffered from either high myopia or ectopia
lentis. Twenty-six (90%) patients exhibited osteopo-
rosis, scoliosis, or Marfanoid features, and 13 (45%)
patients had complications in the vascular system. The
CNS was involved in 16 (55%) patients, and psychiatric
illness was noticed in only 4 (14%) patients. No signif-
icant differences in clinical presentation of CBS defi-
ciency were observed between I278T homozygotes and
patients with other genotypes (data not shown).
Biochemical Characteristics at Diagnosis
At diagnosis, non–protein-bound homocysteine con-
centrations had been measured in 21 patients and total
homocysteine concentrations in 6 patients. In two pa-
tients, no baseline homocysteine blood levels were avail-
able; in these two cases the initial diagnosis had been
made in 1975, by means of qualitative examination of
urine only. The mean non–protein-bound homocysteine
concentration was 135 mmol/L (range, 42–266 mmol/L;
) and mean total plasma homocysteine concen-n  21
tration was 240 mmol/L (range, 134–299 mmol/L; n 
). Mean serum methionine concentration was 1306
mmol/L (range, 52–549 mmol/L; ). Homozygotesn  23
for the I278T mutation tended to have a higher mean
homocysteine concentration than homocystinuria pa-
tients with other genotypes ( mmol/L versus160 73
mmol/L non–protein bound; ),116 57 P  .16
whereas methionine concentrations were not signifi-
cantly different between both genotype groups (89
mmol/L versus mmol/L; ).35 152 166 P  .49
Response to Homocysteine-Lowering Treatment
Long-term homocysteine-lowering therapy (mean
term, 13 years [range, 1–29 years]) consisted of maxi-
mally 750 mg pyridoxine. Fifteen (56%) patients were
concomitantly treated with 5 mg folic acid per day, and
eight (30%) patients also with 6 g betaine per day. Only
one patient (17) had a methionine-restricted diet, with
a methionine content of 600 mg/d. Intramuscular injec-
tions with 1 mg hydroxycobalamin every 1–2 mo were
given to four patients, because of the development of a
vitamin B12 deficiency. Two patients could not be fol-
lowed after diagnosis had been made: patient 6 refused
treatment and patient 13 moved to another country.
Hence, follow-up was recorded in 27 (93%) of the pa-
tients with homocystinuria. The mean length of follow-
up was 11 years (range, 1–20 years; ) in homo-n  11
zygotes for the I278T mutation and 16 years (range,
3–27 years; ) in patients with other genotypesn  16
( ).P  .09
Biochemically, pyridoxine treatment resulted in a
marked decrease in homocysteine concentrations of
90% in homozygotes for the I278T mutation and of
67% in patients with other genotypes ( ). Ex-P ! .02
tended intervention with folic acid, with or without be-
taine, further decreased homocysteine concentrations in
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Table 3
Clinical Presentation of CBS Deficiency at Diagnosis
SIBSHIP PATIENT
CLINICAL PRESENTATION
Myopia
Ectopia
Lentis
Osteo-
porosis Scoliosis
Marfanoid
Featuresa
Arterio-
sclerosisb
Thrombo-
embolismc
Mental
Retardationd Convulsions Psychosis Depression
1 1           
2           
3           
2 4           
5           
3 6           
7           
4 8           
9           
5 10           
11           
6 12           
13           
7 14           
15           
8 16           
9 17           
10 18           
11 19           
12 20           
13 21           
14 22           
15 23           
16 24           
17 25           
18 26           
19 27           
20 28           
21 29           
a Manifested by at least extreme height and arachnodactyly.
b Peripheral arterial disease in patients 7, 10–12, and 28; cerebrovascular disease in patients 12 and 25; and coronary artery disease in patients
6 and 28.
c Deep venous thrombosis in patients 1, 7, 19, 23, and 25; pulmonary embolia in patients 9 and 22; and sinus sagittalis thrombosis in patient
21.
d Severe mental retardation in patients 17 and 19; mild mental retardation (not less than 80) in 10 other patients, as indicated.
both genotype groups, by 84% and 47%, respectively
( ). Homocysteine concentrations normalized (i.e.,P ! .05
non–protein-bound homocysteine !20 mmol/L, or total
plasma homocysteine !50 mmol/L) in 21 (78%) of 27
patients. Methionine concentrations decreased in both
genotype groups upon pyridoxine therapy, by 56% and
33%, respectively ( ). Additional treatment withP  .15
folic acid and betaine, to stimulate homocysteine re-
methylation, left methionine concentrations in homo-
zygotes for the I278T mutation virtually unchanged,
whereas methionine levels substantially increased in pa-
tients with other genotypes.
During long-term treatment, 9 (82%) of 11 homo-
zygotes for I278T continuously presented non–protein-
bound homocysteine concentrations !20 mmol/L or total
homocysteine concentrations !50 mmol/L, versus only 6
(38%) of 16 patients with another genotype ( ).P  .06
Mean ( SD) non–protein-bound homocysteine during
long-term follow-up was mmol/L in I278T13 13
homozygotes versus mmol/L in patients with23 18
other genotypes ( ). For total homocysteine levels,P  .31
these concentrations were mmol/L and30 16 67
mmol/L, respectively ( ). Despite extended ther-38 P ! .01
apy, four patients (14, 15, 17, and 18), all without the
I278T mutation, persistently had total plasma homo-
cysteine 1100 mmol/L.
On the basis of genotype classification, 121 patient-
years of treatment were recorded in 11 homozygotes for
the I278T mutation, during which, in one patient (7),
peripheral arteriosclerosis, already present at diagnosis,
proceeded to development of an abdominal aortic an-
eurysm that required vascular surgery. During 257 pa-
tient-years of treatment in patients with another geno-
type, one patient (25) who suffered from a
cerebrovascular event before diagnosis died, at age 42
years, of a myocardial infarction. In summary, in 378
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patient-years of homocysteine-lowering treatment, only
two vascular events were recorded. From the data of
Mudd et al. (1985), an expected number of primary
vascular events of 2 per 25 years can be calculated for
untreated patients. Without treatment in our group of
27 homocystinurics, at least 30 vascular events would
have been expected ( ). During long-term follow-P ! .01
up, no first involvement of any involved organ system
was noticed. Furthermore, no deterioration of clinical
symptoms was recorded, except for recurrent depressive
episodes in two patients (2 and 15).
Discussion
In the present study, 42 independent homocystinuric
alleles were investigated, which led to the identification
of 10 different mutations (table 1). The 833TrC (I278T)
mutation, first recognized by Kozich and Kraus (1992)
in heterozygous state in a pyridoxine-responsive patient,
was found to be the most prevalent mutation in Dutch
homocystinurics: 23 (55%) of the 42 independent Dutch
homocystinuric alleles carried this mutation.
Seven mutated constructs have thus far been func-
tionally assayed in an E. coli expression system, which
shows that all mutations tested, except D444N (Kluijt-
mans et al. 1996a), had a detrimental effect on CBS
activity. The latter indicates that these mutations are
likely disease-causing ones and not benign polymor-
phisms. The R125W and T434N mutations, detected in
the two siblings of pedigree 7, still need to be analyzed
in an expression system. Another mutation (R125Q) af-
fecting the same arginine residue has been found inde-
pendently by two other groups and was shown to in-
activate CBS completely (Marble et al. 1994; Sebastio
et al. 1995). The R369C and R491C mutations in cis
showed a relatively high residual CBS activity of ∼10%
of the control mean and are compatible with a relatively
late onset of disease. Recently, R369C was postulated
to be a rare polymorphism not affecting CBS function
in a yeast expression system (Kim et al. 1997). The sep-
aration of both mutations by in vitro mutagenesis and
expression in an E. coli expression system will clarify
their individual effect on CBS activity.
We did not detect the 919GrA mutation, which is
very frequent among patients of Celtic origin with pyr-
idoxine-nonresponsive homocystinuria (Gallagher et al.
1995). A 797GrA mutation, a frequent cause of pyri-
doxine-responsive homocystinuria in Norwegian pa-
tients (Kim et al. 1997), was also not observed in these
Dutch patients with homocystinuria. In a survey of 14
Italian families with predominantly pyridoxine-respon-
sive homocystinuria patients, Sebastio et al. (1995) also
did not detect the Celtic 919GrA mutation and fre-
quently observed the 833TrC and 341CrT transitions
(in 9 and 4 of 36 alleles, respectively). Unlike 833TrC,
the other common CBS mutations may be of more recent
genetic origin and have not spread through different
populations yet. On the other hand, our observation of
different haplotypes in homozygotes for 833TrC mu-
tation indicates that there is not one common ancestor
haplotype in these Dutch patients (data not shown).
At diagnosis, no significant differences were observed
in either biochemical or clinical expression of homo-
cystinuria between homozygotes for I278T and patients
with another genotype. Obviously, the homocystinuric
phenotype is not only dependent on CBS genotype but
is also influenced by other genetic and/or environmental
factors. Recently, both factor V Leiden (Mandel et al.
1996) and thermolabile methylenetetrahydrofolate re-
ductase (Kluijtmans et al. 1998) have been postulated
as genetic factors modifying thromboembolic risk in
homocystinurics, and, obviously, other factors may exist
as well. Furthermore, although we did not observe mul-
tiple mutations in cis by sequencing analysis (except in
patient 22), additional mutations in certain alleles might
have influenced our genotype-phenotype correlation and
might explain why our I278T homozygotes are more
severely affected than those described by Shih et al.
(1995).
In the present study, we subdivided our patients into
only two groups with regard to pyridoxine responsive-
ness, to maintain statistical power in our analysis. On
the basis of their biochemical in vivo response to large
doses of pyridoxine, 48% ( ) of the Dutch hom-n  14
ocystinurics were categorized as responsive and 31%
( ) as nonresponsive. However, according to then  9
classification of Brenton and Cusworth (1971), only two
(7%) patients (17 and 18) of these nine would be un-
equivocal nonresponders; the others (24%) would be
considered partially pyridoxine responsive. Not only do
our observations strongly deviate from those of Mudd
et al. (1985), who observed virtually equal proportions
of pyridoxine-responsive and -nonresponsive patients,
but they also clearly indicate the relatively mild nature
of CBS deficiency in the Netherlands. The absence, in
the Netherlands, of a newborn screening program for
homocystinuria, by which patients with pyridoxine-non-
responsive homocystinuria, in particular, are detected
(Mudd et al. 1985, 1995), might have contributed to
this aberrant distribution. Nonresponders may have re-
mained undiagnosed and lost to follow-up, because of
early mortality or admittance to an institution for men-
tally retarded patients. The high prevalence of I278T
among Dutch patients with homocystinuria might also
explain the high pyridoxine responsiveness among these
individuals. Seven homozygotes for this mutation
showed pyridoxine responsiveness, and three individuals
were classified as nonresponders. The latter finding
seems to be in contradiction with the finding of pyri-
doxine responsiveness in three homocystinuria patients
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homozygous for the I278T mutation reported elsewhere
(Sebastio et al. 1995; Shih et al. 1995), although in those
reports no clear definitions of responsiveness were pro-
vided. The homocysteine concentrations upon pyridox-
ine treatment in our I278T homozygotes classified as
nonresponders were only marginally above the cut-off
values of 20 mmol/L (i.e., 28 mmol/L and 32 mmol/L,
non–protein-bound homocysteine) or 50 mmol/L (i.e., 61
mmol/L, total plasma homocysteine) and completely nor-
malized upon extended treatment. So, in the present
study, all homozygotes for the I278T mutation re-
sponded very successfully to homocysteine-lowering
treatment in contrast to non-I278T homozygotes, of
whom only 7 of 17 patients showed such beneficial bi-
ochemical response.
Homocysteine concentrations during long-term treat-
ment showed a clear distinction between both genotype
groups. Homozygotes for the I278T mutation not only
had a lower mean plasma homocysteine concentration
than patients with another genotype, but, on this ex-
tended treatment, the majority of this group continu-
ously had non–protein-bound homocysteine levels !20
mmol/L or total plasma homocysteine !50 mmol/L. In
the other genotype group, the majority of the patients
persistently exceeded these limits.
Cruysberg (1996) reported that long-term therapy of
Dutch homocystinurics prevented the development and
progression of myopia and ectopia lentis. None of the
patients without ectopia lentis at diagnosis developed
this abnormality during follow-up. Furthermore, there
was no progression in the degree of myopia in myopic
patients. The clinical beneficial effect of the homocy-
steine-lowering treatment was also obvious from the
overall number of vascular accidents after start of treat-
ment. Only two vascular accidents were recorded in 378
patient-years of treatment, whereas, if untreated, at least
30 would have been expected ( ), according to theP ! .01
clinical data on the natural history in homocystinuria
presented elsewhere by Mudd et al. (1985). Moreover,
skeletal abnormalities presented at diagnosis in high fre-
quencies in these patients did not deteriorate during this
follow-up period. Osteoporosis persisted in most cases
but did not worsen, and no pathological fractures were
observed (G. H. J. Boers, unpublished data). A longer
follow-up in both genotype groups will be necessary to
determine whether I278T homozygotes respond clini-
cally more favorably to homocysteine-lowering treat-
ment than do other patients with homocystinuria.
In summary, the I278T mutation is the most predom-
inant mutation among Dutch homocystinurics. At di-
agnosis, no significant differences in clinical and bio-
chemical expression were noticed between patients of
both genotype groups, but homozygotes for I278T
showed a higher sensitivity to homocysteine-lowering
treatment by pyridoxine with or without folic acid and
betaine. The clinical efficacy of such therapy in homo-
cystinurics emphasizes the necessity to diagnose CBS de-
ficiency and initiate treatment as early as possible, to
reduce the risk of cardiovascular disease and other se-
quelae of this inborn error of methionine metabolism.
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